Skip to main content
United Therapeutics Corporation (UTHR)
NASDAQ: UTHR · Real-Time Price · USD
489.31
+5.21 (1.08%)
At close: Dec 5, 2025, 4:00 PM EST
492.36
+3.05 (0.62%)
After-hours: Dec 5, 2025, 5:31 PM EST

Revenue

Fiscal year is January - December.
Fiscal Year
 TTM FY 2024 FY 2023 FY 2022 FY 2021 2013 - 2020
Period Ending
 Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 2013 - 2020
Tyvaso Revenue
1.83B1.62B
Log In
Log In
Log In
Upgrade
Remodulin Revenue
533.30M538.10M
Log In
Log In
Log In
Upgrade
Orenitram Revenue
483.50M434.30M
Log In
Log In
Log In
Upgrade
Unituxin Revenue
232.00M238.70M
Log In
Log In
Log In
Upgrade
Adcirca Revenue
26.90M23.80M
Log In
Log In
Log In
Upgrade
Total Product Sales Revenue
3.11B2.86B
Log In
Log In
Log In
Upgrade
Revenue (Other)
22.90M22.10M
Log In
Log In
Log In
Upgrade
Revenue (Total)
3.13B2.88B
Log In
Log In
Log In
Upgrade

Revenue by Geography

Fiscal year is January - December.
Fiscal Year
 TTM FY 2024 FY 2023 FY 2022 FY 2021 2013 - 2020
Period Ending
 Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 2013 - 2020
United States Revenue
2.99B2.74B
Log In
Log In
Log In
Upgrade
Rest-of-World Revenue
138.50M137.70M
Log In
Log In
Log In
Upgrade
Revenue (Total)
3.13B2.88B
Log In
Log In
Log In
Upgrade

Gross Profit

Fiscal year is January - December.
Fiscal Year
 TTM FY 2024 FY 2023 FY 2022 FY 2021 2013 - 2020
Period Ending
 Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 2013 - 2020
Tyvaso Gross Profit
1.61B1.44B
Log In
Log In
Log In
Upgrade
Remodulin Gross Profit
478.70M490.70M
Log In
Log In
Log In
Upgrade
Orenitram Gross Profit
456.00M405.90M
Log In
Log In
Log In
Upgrade
Unituxin Gross Profit
218.20M224.30M
Log In
Log In
Log In
Upgrade
Adcirca Gross Profit
15.40M13.70M
Log In
Log In
Log In
Upgrade
Total Product Sales Gross Profit
2.78B2.57B
Log In
Log In
Log In
Upgrade
Gross Profit (Other)
-9.90M-4.80M
Log In
Log In
Log In
Upgrade
Gross Profit (Total)
2.77B2.57B
Log In
Log In
Log In
Upgrade